Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. David P. Summers who wrote (924)	5/29/1998 2:11:00 PM
From: Brenda L. Greer	Read Replies (1) \| Respond to of 2887

Dr. David P. Summers: Are you the same Dr. David Summers that was Chief Scientific Officer when you left ABMI? Thank you! Steve Rash for all your hard work you have done for ABMI! I'm happy to be a shareholder of ABMI! GO ABMI! Brenda L. Greer

To: Dr. David P. Summers who wrote (924)	5/29/1998 9:05:00 PM
From: Ray Tarke	Respond to of 2887

ABMI is a Buy ! Lets be honest. Can we trust an individual(ex-officer - maybe going Postal) whose first post in S.I in the thread was to put the wool over your eyes, Until Brenda brought him out. << Good afternoon...I am new to this board, but I have owned this stock over a year. I would like hear somnething good since I am $1.00 under water.>> What a great Lie for his first post from the Founder ! Folks, Brenda is looking out for the best interest of all ABMI stockholders. David, this is a great buying opportunity.. buy all you can " ABMI is a Winner " I am Buying more Monday is not going stay this Low too long !! ABMI will be higher next week. Regards, R.T * Brenda, Thank you for all your hard work.

To: Dr. David P. Summers who wrote (924)	5/29/1998 9:48:00 PM
From: Jeffrey L. Henken	Respond to of 2887

David don't you think American BioMed's 100% Silicone Catheters offer some terrific advantages? I suppose you should know wouldn't you? But for those who don't let make a table and show some of the benefits of American BioMed's Cathlab catheters compared to traditional latex or PVC catheters: CATHLAB Features & Benefits Cathlab Silicone Latex/PVC Embolectomy Catheters Embolectomy Catheters Superior biocompatibility Very Limited compatibility Non-toxic Toxic with time 3 year shelf life 27 month shelf life Non-fragmentation of balloon Fragmentation is a potential problem Silicone balloon is an Latex balloon is glued or integral part of silicone shaft sutured onto the shaft Virtually no possibility of Potential problem of dislodgement balloon dislodgement is much higher Uninterrupted balloon Interrupted balloon transition transition I have to tell you it's easy to see why American BioMed has successfully rounded out their North American distributor network. We're not just talking about a catheter that won't initiate a potentially severe allergic reaction in patients who are sensitive to latex! No much more than that, American BioMed's catheters are simply better designed. GO ABMI! Regards, Jeff

To: Dr. David P. Summers who wrote (924)	5/29/1998 10:31:00 PM
From: Jeffrey L. Henken	Respond to of 2887

David did you ever read this study by Dr Samuel S Ahn? A PROSPECTIVE, RANDOMIZED STUDY COMPARING THE IMMEDIATE EFFECTIVENESS OF American BioMed, Inc., THROMBECTOMY CATHETERS VERSUS THE BAXTER BALLOON CATHETER PURPOSE: To conduct a prospective, randomized study to compare the immediate effectiveness of American BioMed balloon thrombectomy catheters versus the Baxter balloon thrombectomy catheter. MATERIALS AND METHODS: Twenty consecutive patients with thrombosed vessels and/or ateriovenous fistulas underwent a thrombectomy procedure. Ten patients were randomized to thrombectomy with American BioMed balloons, and ten to thrombectomy with the Baxter Fogarty balloon catheter. Intraoperative data collected included the number of catheters used per case, the number of passes made per catheter, and the number of balloon ruptures. The immediate outcome of each procedure was measured by both radiological(angiogram) and clinical parameters and the procedure was deemed an initial success if patency of the conduit was initially restored. RESULTS: Twenty thrombectomies were performed over a six-month period. Eleven(55%) thrombectomies were performed in native peripheral arteries or bypass grafts, while nine(45%) were completed in hemodialysis arteriovenous PTFE graft fistulas. A mean of 1.4 Baxter catheters were used compared to 1.2 American BioMed catheters per case(range 1-2). With American BioMed catheters, a mean of 4.2(range 1-8) passes were made per catheter. An average of 3.9(range 1-10) passes per catheter experienced balloon ruptures, while only 1(8.3%) of 12 American BioMed catheters ruptured. All procedures performed with American BioMed and all thrombectomies performed with the Baxter balloon enjoyed initial technical success. The clinical success rate for both American BioMed and Baxter Fogarty balloons was 90% due to the fact that one patient from each group required removal of an infected arteriovenous PTFE graft. There were no complications in either group. CONCLUSION:Thrombectomies performed with American BioMed catheters resulted in a lower mean number of catheters used per case. We attribute this lower mean number of catheters per case to the statistically significant(p<0.05) decreased frequency of rupture of American BioMed catheters when compared to the Fogarty balloon. There was no significant difference between the immediate success rates of the two devices. We conclude that while the two devices have comparable immediate effectiveness, thrombectomy with American BioMed balloons reduce the number of catheters needed, thus possibly reducing the time and cost of thrombectomy procedures. Sounds like another great reason why American BioMed has seen an a very real and measurable increase in catheter sales year over year the last two quarters. They make better catheters that can save time and money for physicians and these catheters are much safer for their patients. Regards, Jeff